Come and find out what we have in the pipeline and explore those indications where our technology is set to have the greatest clinical benefit.
Home - Pipeline
What's in the pipeline?
Active ingredient
Mechanism
Indication
Pre-clinical discovery
Pre-clinical development
Phase I/IIa
Phase IIb
Phase III
Status
allo-APZ2 1
Anti-Inflammation
RDEB a b d
On hold
allo-APZ2 1
Anti-Inflammation
Non-healing chronic venous wounds (CVU) 4
Recruiting
allo-APZ2 1
Anti-Inflammation
Non-healing diabetic foot ulcers (DFU)
On hold
LSC2 3
Regeneration
LSCD a b c
On hold
APZ2 2
Anti-Inflammation
Non-healing chronic venous wounds (CVU)
Closed
allo-APZ2 1
Anti-Inflammation
ACLF
Closed
1 Allogeneic ABCB5-positive mesenchymal stem cells
2 Autologous ABCB5-positive mesenchymal stem cells
3 Allogeneic ABCB5-positive limbal stem cells
4 Marketing authorization in Germany granted for AMESANAR®
a Orphan Drug Designation FDA
b Orphan Drug Designation EMA
c Fast Track Designation FDA
d Pediatric Investigation Plan (PIP) approved by PDCO (EMA)